Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 6/20 | 0.44 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.36 |
| ▸ | BAD | Q92934 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8661517 | 0.82 | CES1 (0.43) | CES1NOS3NOS1NOS2BCL2L1 | |
| SCHEMBL1278375 | 0.76 | BCL2L1 (0.52) | CES1NOS3NOS1NOS2BCL2L1 | |
| SCHEMBL9461283 | 0.74 | BCL2L1 (0.50) | CES1NOS3NOS1NOS2BCL2L1 | |
| SCHEMBL13346281 | 0.73 | CES1 (0.47) | CES1NOS3NOS1NOS2BCL2L1 | |
| SCHEMBL23944932 | 0.71 | PARP1 (0.46) | CES1NOS3NOS1NOS2BCL2L1 | |
| SCHEMBL22266013 | 0.70 | — | — | |
| Hydrochloric Acid SCHEMBL11039603 | 0.69 | NOS3 (0.38) | CES1NOS3NOS1NOS2 | |
| SCHEMBL953470 | 0.67 | CES1 (0.53) | CES1NOS3NOS1NOS2BCL2L1 | |
| SCHEMBL2972319 | 0.67 | NLRP3 (0.34) | — | |
| SCHEMBL8663172 | 0.66 | BCL2L1 (0.43) | CES1NOS3NOS1NOS2BCL2L1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11040995-B2 | Catalyst comprising a metallocene complex and co-catalyst | SABIC GLOBAL TECHNOLOGIES B.V. (NL) | 2021-06-22 | — | — | US | disclosed |
| US-20200270292-A1 | CATALYST COMPRISING A METALLOCENE COMPLEX AND CO-CATALYST | SABIC GLOBAL TECHNOLOGIES B.V. (NL) | 2020-08-27 | — | — | US | disclosed |
| EP-3400230-B1 | CATALYST COMPRISING A METALLOCENE COMPLEX AND A CO-CATALYST | SABIC GLOBAL TECHNOLOGIES BV (NL) | 2019-09-11 | — | — | EP | disclosed |
| EP-3400230-A1 | CATALYST COMPRISING A METALLOCENE COMPLEX AND A CO-CATALYST | SABIC Global Technologies B.V. (NL) | 2018-11-14 | — | — | EP | disclosed |
| WO-2017118617-A1 | CATALYST COMPRISING A METALLOCENE COMPLEX AND A CO-CATALYST | SABIC GLOBAL TECHNOLOGIES B.V. (NL) | 2017-07-13 | — | — | WO | disclosed |
| EP-1257541-B1 | POLYPHARMACOPHORIC AGENTS | MOLECULAR INSIGHT PHARM INC (US) | 2008-09-03 | — | — | EP | disclosed |
| US-20070129440-A1 | Polypharmacophoric agents | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2007-06-07 | — | — | US | disclosed |
| US-7141573-B2 | Polypharmacophoric agents | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2006-11-28 | — | — | US | disclosed |
| EP-1257541-A2 | POLYPHARMACOPHORIC AGENTS | Biostream Therapeutics (US) | 2002-11-20 | — | — | EP | disclosed |
| US-20020042357-A1 | Polypharmacophoric agents | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2002-04-11 | — | — | US | disclosed |
| WO-2001051474-A2 | POLYPHARMACOPHORIC AGENTS | BIOSTREAM THERAPEUTICS, INC. (US) | 2001-07-19 | — | — | WO | disclosed |
| EP-0870759-B1 | Aminated 6,7,8,9-tetrahydro-cyclopenta[a]naphtalene- and 2,3-dihydro-cyclopenta[e]indene-derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR (FR) | 2001-03-21 | — | — | EP | disclosed |
| EP-0870759-B1 | Aminated 6,7,8,9-tetrahydro-cyclopenta[a]naphtalene- and 2,3-dihydro-cyclopenta[e]indene-derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR (FR) | 2001-03-21 | — | — | EP | disclosed |
| CN-1207384-A | Amino compounds of 6,7,8,9-tetrahydro-cyclopenta[a]naphthalene and of 2,3-dihydro-cyclopenta[e]indene | ADIR (FR) | 1999-02-10 | — | — | CN | disclosed |
| EP-0870759-A1 | Aminated 6,7,8,9-tetrahydro-cyclopenta[a]naphtalene- and 2,3-dihydro-cyclopenta[e]indene-derivatives, process for their preparation and pharmaceutical compsitions containing them | ADIR ET COMPAGNIE (FR) | 1998-10-14 | — | — | EP | disclosed |
| EP-0870759-A1 | Aminated 6,7,8,9-tetrahydro-cyclopenta[a]naphtalene- and 2,3-dihydro-cyclopenta[e]indene-derivatives, process for their preparation and pharmaceutical compsitions containing them | ADIR ET COMPAGNIE (FR) | 1998-10-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11040995-B2 | Catalyst comprising a metallocene complex and co-catalyst | CCRL2, UBE2L3, MAL2 | CES1 4454/4885NOS3 2975/4885NOS1 3924/4885 |
| US-20200270292-A1 | CATALYST COMPRISING A METALLOCENE COMPLEX AND CO-CATALYST | LAS1L, CCNE2, CKS2 | CES1 4424/4885NOS3 3245/4885NOS1 4062/4885 |
| US-20020042357-A1 | Polypharmacophoric agents | COMT, SLC6A3, HTR3C | CES1 1139/4885NOS3 1503/4885NOS1 2227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.